Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms - Sausville, E A; Arbuck, S G; Messmann, R; Headlee, D; Bauer, K S; Lush, R M; Murgo, A; Figg, W D; Lahusen, T; Jaken, S; Jing, X; Roberge, M; Fuse, E; Kuwabara, T; Senderowicz, A M (J Clin Oncol, 2001)